PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China; Department of Infectious Disease, Peking University International Hospital, Beijing, China.\', \'Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China.\', \'Department of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, China.\', \'Administrative Office, Wuhan Pulmonary Hospital, Wuhan, China.\', \'Department of Infectious Disease, Ezhou Central Hospital, Ezhou, China.\', \'Department of Internal Medicine, Fankou Branch of Ezhou Central Hospital, Ezhou, China.\', \'Department of Obstetrics and Gynecology, Fankou Branch of Ezhou Central Hospital, Ezhou, China.\', \'Department of Hepatology III, The Third People\'s Hospital of Shenzhen, Shenzhen, China.\', \'Department of Respiratory Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.\', \'Department of Respiratory Medicine, Bengbu Fifth People\'s Hospital, Bengbu, China.\', \'Department of Respiratory Medicine, Wuxi Fifth People\'s Hospital, Wuxi, China.\', \'Administrative Office, The Third People\'s Hospital of Shenzhen, Shenzhen, China. Electronic address: yingxialiu@hotmai.com.\', \'Administrative Office, Wuhan Pulmonary Hospital, Wuhan, China. Electronic address: PengPengwg@126.com.\', \'Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China; Department of Infectious Disease, Peking University International Hospital, Beijing, China. Electronic address: john131212@126.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1567-5769(21)00338-610.1016/j.intimp.2021.107702
?:doi
?:hasPublicationType
?:journal
  • International immunopharmacology
is ?:pmid of
?:pmid
?:pmid
  • 33930706
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.051
?:rankingScore_hIndex
  • 94
is ?:relation_isRelatedTo_publication of
?:title
  • Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33930706>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33930706>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all